PTPRN2 Antibody

What is PTPRN2 and why is it significant in research?

PTPRN2 (Protein Tyrosine Phosphatase, Receptor Type, N Polypeptide 2) is a tyrosine phosphatase-like protein predominantly expressed in endocrine and neuronal cells, where it functions in exocytosis. The significance of PTPRN2 extends beyond its normal physiological role, as its immature isoform proPTPRN2 has been found to be overexpressed in various cancers, including breast cancer. High proPTPRN2 expression has been strongly associated with lymph node-positive breast cancer and poor clinical outcomes, suggesting its potential role in cancer progression and metastasis. Understanding PTPRN2 function is crucial for researchers investigating cancer biology, diabetes, and neurological disorders, making PTPRN2 antibodies essential tools for such studies .

What are the molecular characteristics of PTPRN2?

PTPRN2 is a protein with a calculated molecular weight of approximately 111 kDa, consisting of 1015 amino acids. Its gene is identified by GenBank Accession Number BC034040 and NCBI Gene ID 5799. The protein is encoded by the PTPRN2 gene and is also referred to by its UNIPROT ID Q92932. PTPRN2 belongs to the family of protein tyrosine phosphatases, specifically receptor-type phosphatases, which are involved in regulating cellular signaling through dephosphorylation of tyrosine residues on target proteins. The protein's structure includes transmembrane domains and a phosphatase domain, although some studies suggest it may have limited catalytic activity compared to other phosphatases .

What species reactivity do PTPRN2 antibodies typically demonstrate?

Most commercially available PTPRN2 antibodies show reactivity with human, mouse, and rat samples, making them versatile tools for comparative studies across different mammalian models. For instance, the polyclonal antibody catalog number 12576-1-AP has been tested and confirmed to react with human, mouse, and rat samples in ELISA applications . Similarly, other antibodies like ABIN5014206 demonstrate reactivity primarily with human samples in Western Blotting (WB), Immunohistochemistry (IHC), and Immunocytochemistry (ICC) applications . Researchers should carefully verify the specific reactivity of their chosen antibody for their target species, as this can vary between antibody clones and manufacturers, particularly when working with less common model organisms or when cross-species comparisons are critical to experimental design .

What are the primary research applications for PTPRN2 antibodies?

PTPRN2 antibodies serve multiple critical applications in research settings. The most common applications include:

• Western Blotting (WB): For detecting and quantifying PTPRN2 protein expression in cell or tissue lysates. Most PTPRN2 antibodies are validated for WB with recommended dilutions ranging from 0.01-2μg/mL depending on the specific antibody .

• Immunohistochemistry (IHC): For localizing and visualizing PTPRN2 in tissue sections, typically used at concentrations of 5-20μg/mL .

• Immunocytochemistry (ICC): For detecting PTPRN2 in cultured cells, with similar concentration ranges as IHC (5-20μg/mL) .

• ELISA: For quantitative detection of PTPRN2 in solution. Several antibodies, such as 12576-1-AP, are specifically validated for ELISA applications .

• Immunoprecipitation (IP): For isolating PTPRN2 protein complexes to study protein-protein interactions .

Researchers should optimize working dilutions for their specific experimental conditions as the optimal concentration may vary depending on sample type, detection method, and experimental goals.

How should researchers validate PTPRN2 antibody specificity in their experimental systems?

Validating antibody specificity is crucial for ensuring reliable experimental results. For PTPRN2 antibodies, researchers should consider implementing the following validation approaches:

• Positive and negative control samples: Use tissues or cell lines with known high expression (e.g., endocrine or neuronal cells) versus those with low/no expression of PTPRN2.

• Knockdown/knockout validation: Compare antibody signal between wild-type samples and those where PTPRN2 has been depleted through siRNA, shRNA, or CRISPR-Cas9 methods. Studies have shown that PTPRN2 depletion significantly reduces invasiveness of colorectal cancer cells in vitro and liver homing and metastasis in vivo, providing both validation of antibody specificity and functional insights .

• Peptide competition assays: Pre-incubate the antibody with the immunizing peptide or recombinant protein before application to samples. If the antibody is specific, this should eliminate or significantly reduce the signal.

• Multiple antibody validation: Use antibodies targeting different epitopes of PTPRN2. For example, compare results between antibodies recognizing amino acids 839-1015 versus those targeting amino acids 22-242 or other regions .

• Correlation with mRNA expression: Validate protein expression patterns detected by the antibody with mRNA expression data from qPCR or RNA-seq experiments.

These validation steps are particularly important when studying PTPRN2 in novel contexts or when contradictory results emerge from different experimental approaches.

What is the significance of PTPRN2 in cancer research?

PTPRN2, particularly its immature isoform proPTPRN2, has emerged as a significant factor in cancer research due to its aberrant expression in various cancer types. Studies have demonstrated that high proPTPRN2 expression is strongly associated with lymph node-positive breast cancer and poor clinical outcomes. The oncogenic properties of proPTPRN2 have been substantiated through both loss-of-function and gain-of-function experiments: loss of proPTPRN2 in breast cancer cells promotes apoptosis and blocks tumor formation in mice, while enforced expression in non-transformed human mammary epithelial cells produces opposite effects .

Mechanistically, proPTPRN2 appears to exert its oncogenic effects through direct interaction with TRAF2, a hub scaffold protein for multiple kinase cascades, including those that activate NF-κB, a key regulator of inflammation and cancer progression. This interaction suggests that proPTPRN2 may influence tumor development and progression by modulating inflammatory signaling pathways .

Furthermore, in colorectal cancer (CRC), high PTPRN2 expression correlates with decreased patient survival. Mechanistic studies have shown that PTPRN2 depletion significantly reduces invasiveness of CRC cells in vitro and liver homing and metastasis in vivo through dysregulation of epithelial-mesenchymal transition and a decrease in insulin receptor signaling pathway activity . These findings collectively position PTPRN2 as both a potential biomarker and therapeutic target in cancer research.

How does PTPRN2 connect diabetes and cancer research?

The intersection of PTPRN2 in diabetes and cancer research represents an intriguing area of investigation. While PTPRN is well-established as an autoantigen in type 1 diabetes (T1D), recent research has uncovered a notable connection between PTPRN autoantibodies and colorectal cancer (CRC) risk in patients with type 2 diabetes (T2D).

Studies have shown that plasma autoantibodies against PTPRN (either full-length or selected domains) can discriminate between T2D patients with and without CRC. This suggests that PTPRN autoantibodies may serve as valuable diagnostic markers for stratifying T2D patients who are at high risk for developing CRC, potentially enabling earlier intervention and improved clinical outcomes .

The mechanistic link between PTPRN, diabetes, and cancer likely involves dysregulation of receptor tyrosine kinase signaling, which is common to both diseases. PTPRN depletion has been shown to decrease insulin receptor signaling pathway activity in cancer cells, suggesting that PTPRN may contribute to the well-established co-occurrence correlation between diabetes and certain cancers, particularly CRC .

This intersection highlights the potential of PTPRN as a therapeutic target in patients with comorbid diabetes and cancer, and underscores the value of PTPRN antibodies in both basic research and potential clinical applications for disease monitoring.

What methodology should researchers use when studying PTPRN2 autoantibodies in disease contexts?

When investigating PTPRN2 autoantibodies in disease contexts such as diabetes or cancer, researchers should implement a comprehensive methodological approach:

• Sample selection and cohort design: Establish clearly defined patient cohorts, including individuals with type 2 diabetes (T2D), colorectal cancer (CRC), both diseases, and healthy controls. This design enables comparative analysis of autoantibody profiles across disease states .

• Autoantibody detection methods:

  • ELISA: Develop assays using recombinant PTPRN2 (full-length or specific domains) as the capture antigen to quantify autoantibody levels in plasma or serum samples.

  • Western blotting: Use to confirm the specificity of autoantibody binding to PTPRN2.

  • Immunoprecipitation: Employ to isolate PTPRN2-autoantibody complexes from patient samples.

• Domain-specific analysis: Test autoantibodies against different domains of PTPRN2 separately, as research has shown that reactivity against specific protein regions may correlate more strongly with certain disease states .

• Clinical correlation: Correlate autoantibody levels with clinical parameters such as disease progression, treatment response, and patient survival to establish their prognostic or predictive value.

• Functional validation: Investigate the biological effects of patient-derived autoantibodies on PTPRN2 function in relevant cell culture models to understand whether these autoantibodies directly modulate PTPRN2 activity or merely serve as biomarkers.

• Statistical analysis: Apply appropriate statistical methods to assess the discriminatory power of PTPRN2 autoantibodies, including sensitivity, specificity, and receiver operating characteristic (ROC) curve analysis.

This methodological framework enables researchers to rigorously evaluate the potential of PTPRN2 autoantibodies as diagnostic markers for stratifying T2D patients at high risk of developing CRC, potentially facilitating earlier intervention strategies .

How can researchers distinguish between proPTPRN2 and mature PTPRN2 in experimental systems?

Distinguishing between proPTPRN2 (the immature isoform) and mature PTPRN2 is critical for cancer research, as proPTPRN2 has been specifically implicated in oncogenic processes. Researchers can employ several approaches to differentiate between these isoforms:

• Antibody selection: Use antibodies that specifically recognize epitopes unique to either proPTPRN2 or mature PTPRN2. For example, antibodies targeting regions that are cleaved during maturation would identify only the proform.

• Molecular weight discrimination: On Western blots, proPTPRN2 and mature PTPRN2 can be distinguished by their different molecular weights. The calculated molecular weight of full-length PTPRN2 is approximately 111 kDa (1015 amino acids) , but the mature form will appear smaller due to post-translational processing.

• Subcellular fractionation: The immature proform is typically found in different cellular compartments (e.g., endoplasmic reticulum, Golgi) compared to the mature form (plasma membrane, secretory vesicles). Subcellular fractionation followed by Western blotting can help distinguish between these populations.

• Glycosylation analysis: Treatment with specific glycosidases can help differentiate between immature and mature forms based on their distinct glycosylation patterns, which change during protein maturation.

• Pulse-chase experiments: To track the conversion of proPTPRN2 to mature PTPRN2, researchers can perform pulse-chase experiments with metabolic labeling, which allows visualization of the protein maturation process over time.

Understanding the specific form of PTPRN2 being studied is particularly important given research showing that high proPTPRN2 expression specifically (not total PTPRN2) is associated with lymph node-positive breast cancer and poor clinical outcomes .

What experimental controls should be implemented when studying PTPRN2's role in cancer metastasis?

When investigating PTPRN2's role in cancer metastasis, robust experimental controls are essential for generating reliable and reproducible results:

• Expression validation controls:

  • Positive controls: Include cell lines or tissues known to express high levels of PTPRN2.

  • Negative controls: Use cell lines with confirmed low/no PTPRN2 expression or those with CRISPR-mediated PTPRN2 knockout.

  • Antibody validation: Confirm antibody specificity using peptide competition or multiple antibodies targeting different epitopes.

• Functional studies controls:

  • Multiple knockdown approaches: Use both siRNA and shRNA approaches to ensure observed phenotypes are not due to off-target effects.

  • Rescue experiments: Re-express PTPRN2 in knockdown models to confirm phenotype reversal, which establishes causality.

  • Domain mutants: Use mutants lacking specific functional domains to identify which regions of PTPRN2 are critical for the observed metastatic phenotypes.

• In vivo metastasis model controls:

  • Cell line authentication: Ensure cancer cell lines used for metastasis studies are authenticated and regularly tested for mycoplasma contamination.

  • Multiple metastasis models: Compare results between different metastasis models (e.g., tail vein injection, orthotopic implantation) to ensure robustness of findings.

  • In vivo imaging controls: For bioluminescence or fluorescence imaging of metastasis, include appropriate background controls and standardize signal quantification.

• Mechanistic investigation controls:

  • Pathway validation: When studying PTPRN2's impact on signaling pathways like epithelial-mesenchymal transition or insulin receptor signaling, include both upstream and downstream markers to confirm pathway dysregulation.

  • Interaction controls: For studies investigating PTPRN2's interaction with proteins like TRAF2, include non-interacting protein controls and reciprocal immunoprecipitation approaches .

Implementation of these controls is particularly important given the observed effects of PTPRN2 depletion on reducing invasiveness of colorectal cancer cells in vitro and liver homing and metastasis in vivo .

How might PTPRN2 function as a therapeutic target in cancer treatment?

PTPRN2, particularly its immature isoform proPTPRN2, shows considerable promise as a therapeutic target in cancer treatment based on several key findings from recent research:

• Selective oncogenic activity: Unlike many potential cancer targets, proPTPRN2 appears to be aberrantly expressed in cancer cells but shows limited expression in normal adult tissues outside of endocrine and neuronal cells. This selective expression pattern potentially offers a therapeutic window that could minimize off-target effects .

• Critical role in tumor survival: Loss-of-function studies have demonstrated that depletion of proPTPRN2 in breast cancer cells promotes apoptosis and blocks tumor formation in mice, suggesting that targeting proPTPRN2 could directly impact tumor cell viability .

• Impact on metastatic potential: PTPRN2 depletion significantly reduces the invasiveness of colorectal cancer cells in vitro and liver homing and metastasis in vivo, indicating that targeting PTPRN2 might not only affect primary tumors but could also inhibit metastatic spread .

• Defined molecular interactions: ProPTPRN2 appears to exert its oncogenic effects through direct interaction with TRAF2, a hub scaffold protein for multiple kinase cascades including NF-κB activation. This defined molecular interaction provides a specific mechanism that could be targeted therapeutically .

• Potential combination approaches: Given PTPRN2's role in dysregulating the epithelial-mesenchymal transition and decreasing insulin receptor signaling pathway activity, combination therapies targeting PTPRN2 alongside these pathways might offer synergistic effects .

Therapeutic approaches might include:

• Small molecule inhibitors targeting the interaction between proPTPRN2 and TRAF2

• Antibody-drug conjugates utilizing PTPRN2 antibodies to deliver cytotoxic payloads to cancer cells

• RNA interference or antisense oligonucleotides to downregulate PTPRN2 expression

• PROTAC (Proteolysis Targeting Chimera) approaches to induce selective degradation of PTPRN2

These therapeutic strategies represent promising directions for translating basic research findings on PTPRN2 into clinical applications for cancer treatment.

What are the challenges in developing standardized PTPRN2 detection methods across research laboratories?

The development of standardized PTPRN2 detection methods across research laboratories faces several significant challenges that researchers must address to ensure reproducible and comparable results:

• Antibody variability:

  • Different epitope recognition: Various commercial antibodies target different regions of PTPRN2 (e.g., AA 839-1015, AA 22-242, AA 108-212) , potentially yielding different results depending on protein conformation or post-translational modifications.

  • Clone-to-clone variability: Even antibodies targeting the same region may show different sensitivities and specificities based on their production methods and source animals.

  • Lot-to-lot variation: Manufacturing inconsistencies can lead to performance differences between antibody lots from the same supplier.

• Isoform complexity:

  • Detecting specific isoforms: Distinguishing between proPTPRN2 and mature PTPRN2 requires carefully selected antibodies and experimental conditions.

  • Post-translational modifications: Glycosylation and phosphorylation states may affect antibody recognition and vary across cell types and conditions.

• Protocol optimization challenges:

  • Application-specific conditions: Optimal antibody concentrations differ significantly between applications (0.01-2μg/mL for WB versus 5-20μg/mL for IHC/ICC) .

  • Sample preparation variability: Different fixation methods, buffer compositions, and processing times can affect epitope accessibility and antibody binding.

• Validation standards:

  • Lack of universal positive controls: No universally accepted reference standard or positive control exists for PTPRN2 detection.

  • Knockout validation limitations: Not all laboratories have access to PTPRN2 knockout models for definitive antibody validation.

• Reporting inconsistencies:

  • Incomplete methodology documentation: Publications often lack detailed protocols for PTPRN2 detection, hindering reproducibility.

  • Insufficient antibody characterization: Many studies do not comprehensively report antibody validation steps or specificity tests.

To address these challenges, the field would benefit from:

• Development of reference standards for PTPRN2 detection

• Multicenter validation studies comparing different antibodies and detection protocols

• Detailed reporting guidelines for PTPRN2 detection methodology

• Repositories of validated PTPRN2 knockout and overexpression controls

Implementing these strategies would significantly enhance reproducibility and cross-laboratory comparability in PTPRN2 research.